Article -> Article Details

1. Introduction

Neurological disorders such as stroke, traumatic brain injury (TBI), and dementia are among the most challenging medical conditions worldwide. These disorders affect memory, movement, speech, attention, and independence, often leaving patients and families facing long-term emotional and physical burdens. Despite decades of research, treatments capable of protecting and repairing damaged brain tissue remain limited.

Among the emerging approaches in neurological care, one brain-derived neuropeptide therapy has gained global attention for its neuroprotective and neurorestorative potential. Widely known as Cerebrolysin or Cerebroprotein Hydrolysate, this injectable therapy is derived from purified porcine brain proteins and contains biologically active neuropeptides and amino acids that mimic the brain’s natural growth factors.

Used in more than 50 countries across Europe, Asia, and Latin America, this therapy has been studied extensively in stroke recovery, traumatic brain injury, and dementia-related cognitive decline. Its unique mechanism focuses not only on symptom management but also on supporting neuron survival, brain repair, and neuroplasticity.

2. How the Therapy Works

The human brain has limited regenerative ability. After stroke or traumatic injury, neurons may die permanently, but surviving brain cells can reorganize and form new connections through a process called neuroplasticity. This therapy aims to support that recovery process.

2.1 Neurotrophic Support

Neurotrophic factors are proteins that help neurons grow, survive, and communicate. In disorders like Alzheimer’s disease, stroke, and TBI, these protective factors become depleted.

Research suggests the therapy mimics several important neurotrophic factors, including:

BDNF (Brain-Derived Neurotrophic Factor) – supports memory and learning

NGF (Nerve Growth Factor) – essential for cholinergic neurons affected in Alzheimer’s disease

GDNF (Glial Cell Line-Derived Neurotrophic Factor) – supports motor and dopaminergic neurons

CNTF (Ciliary Neurotrophic Factor) – protects neurons from injury-related stress

This neurotrophic action may help preserve existing neurons while encouraging recovery and adaptation.

3. Protection Against Brain Cell Damage

3.1 Reduction of Excitotoxicity

After an ischemic stroke, the brain releases excessive glutamate, leading to calcium overload inside neurons. This destructive process, called excitotoxicity, rapidly damages brain tissue.

Studies suggest this therapy may:

Stabilize neuronal membranes

Regulate calcium influx

Reduce glutamate toxicity

Limit infarct size in ischemic injury models

These effects are particularly important during the early stages of stroke recovery.

3.2 Anti-Apoptotic Effects

Neurons surrounding an injury site may continue dying for days through apoptosis, or programmed cell death. The therapy appears to suppress apoptotic pathways involving caspase enzymes and Bcl-2 proteins, potentially extending the survival window for vulnerable neurons.

3.3 Neuroplasticity and Synaptic Remodeling

Recovery from neurological injury depends heavily on the brain’s ability to reorganize itself. Research indicates the therapy may:

Increase dendritic spine density

Promote new synaptic connections

Enhance synaptic plasticity

Support cognitive and motor rehabilitation

This may explain why improvements are sometimes observed weeks or months after treatment initiation.

4 Clinical Applications

4.1 Ischemic Stroke

Stroke is one of the leading causes of disability worldwide. In ischemic stroke, blood flow to brain tissue becomes blocked, depriving neurons of oxygen and nutrients.

Clinical studies have shown that patients receiving this neuropeptide therapy alongside standard stroke care may experience:

Faster neurological recovery

Improved motor function

Better rehabilitation outcomes

Enhanced functional independence

Benefits appear greatest when treatment begins within 24–72 hours after stroke onset and continues for 10–30 days.

CASTA Trial

One of the largest clinical studies, the China Stroke Alliance Cerebrolysin Trial (CASTA), evaluated over 1,000 stroke patients. While overall results were mixed, subgroup analyses suggested meaningful benefits in patients with moderate-to-severe strokes.

4.2 Traumatic Brain Injury (TBI)

Traumatic brain injury causes both immediate structural damage and delayed secondary injury processes such as inflammation, oxidative stress, and apoptosis.

Research in TBI patients has reported potential benefits including:

Improved Glasgow Coma Scale (GCS) scores

Faster recovery of consciousness

Better memory and attention outcomes

Enhanced rehabilitation potential

Reduced neuronal damage

Several studies conducted in Europe and Asia have shown promising improvements in functional recovery after moderate-to-severe TBI.

4.3 Alzheimer’s Disease and Dementia

Dementia affects cognition, memory, language, and attention. Alzheimer’s disease remains the most common form.

One important symptom targeted by this therapy is aprosexia, a severe inability to maintain attention and concentration.

Potential Mechanisms in Dementia

Research suggests the therapy may:

Support cholinergic neuron survival

Reduce amyloid-beta accumulation

Slow tau-related neurodegeneration

Enhance synaptic communication

Improve neuroplasticity

Clinical trials have reported improvements in:

Memory and cognition

Attention and concentration

Activities of daily living

Behavioral symptoms such as agitation and irritability

Repeated treatment cycles often appear more beneficial than a single course.

5. Dosage and Administration

The therapy is available as a sterile injectable solution in ampoules of varying strengths.

5.1 Common Treatment Protocols

Condition Typical Dosage

Acute Ischemic Stroke 10–30 mL IV daily for 10–21 days

Traumatic Brain Injury 10–50 mL IV daily

Alzheimer’s Disease 5–30 mL IV daily for 20–30 days

Vascular Dementia 5–10 mL IM or IV daily

Post-Stroke Rehabilitation 5–10 mL IM daily

5.2 Routes of Administration

Intravenous Infusion (IV):

Preferred for acute neurological conditions

Diluted in saline or Ringer’s solution

Administered slowly over 15–60 minutes

Intramuscular Injection (IM):

Used for lower doses and maintenance therapy

Usually injected into the gluteal muscle

Treatment is commonly given in repeated cycles with rest intervals of 4–8 weeks between courses.

6. Safety Profile and Side Effects

This therapy is generally considered well tolerated in clinical practice.

6.1 Common Side Effects

Mild injection-site pain

Temporary blood pressure fluctuations

Nausea or loss of appetite

Agitation or restlessness

Mild fever

Sleep disturbances

Rare allergic reactions have also been reported.

6.2 Contraindications and Precautions

The therapy should be used cautiously or avoided in:

Active hemorrhagic stroke

Severe epilepsy or seizure disorders

Severe renal impairment

Pregnancy and breastfeeding

Known hypersensitivity to porcine-derived products

Medical supervision is essential during treatment.

7. Drug Interactions

Potential interactions may occur with:

Monoamine oxidase inhibitors (MAOIs)

Antidepressants

Anticonvulsants

Nootropic medications

Acetylcholinesterase inhibitors such as donepezil

Memantine

The therapy should not be mixed directly with other drugs in the same infusion bottle or syringe.

8. Emerging Research and Future Directions

Ongoing research is exploring:

Personalized treatment protocols

Biomarkers predicting treatment response

Combination therapies for Alzheimer’s disease

Parkinson’s disease applications

Post-COVID cognitive impairment

Optimal treatment cycle frequency

As neuroscience advances, therapies focused on neurorestoration and plasticity may become increasingly important in neurological care.

9. Conclusion

Neurological disorders such as stroke, traumatic brain injury, and dementia can profoundly affect quality of life, independence, and emotional well-being. Traditional treatments often focus mainly on symptom management, leaving limited options for actual neuronal repair.

Brain-derived neuropeptide therapy represents a promising neuroprotective and neurorestorative approach designed to support neuron survival, reduce inflammation, improve neuroplasticity, and aid cognitive recovery. Its broad mechanism of action and decades of international clinical experience have made it one of the most discussed therapies in modern neurology.

Although research continues and regulatory acceptance varies globally, the growing body of evidence highlights its potential role in comprehensive neurological rehabilitation programs. For patients and caregivers exploring neurological treatment options, consultation with a qualified neurologist remains essential to determine whether this therapy may be appropriate as part of an individualized care plan.

The brain’s ability to adapt and recover is extraordinary. Therapies that support that healing process may continue shaping the future of neurological medicine.